Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis

source extracted confidence: high 2026-04-09
#humans #proton-pump-inhibitors #constipation #sulfonamides #pyrroles

Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis

Gong et al., 2023 | Rev Esp Enferm Dig | Meta Analysis

Citation

Gong Haiying, Han Di, ... Chen Diping. Adverse events of vonoprazan in the treatments of acid-related diseases: a systematic review and meta-analysis. Rev Esp Enferm Dig. 2023-Jun;115(6):294-300. doi:10.17235/reed.2022.9228/2022

Abstract

BACKGROUND AND AIMS: vonoprazan, a novel potassium-competitive acid blocking agent, has better clinical outcomes in the treatment of acid-related diseases. However, some adverse events have been associated with vonoprazan for the treatment of acid-associated diseases. Therefore, this systematic review and meta-analysis aimed to explore the safety and tolerability of vonoprazan for acid-associated diseases. METHODS: electronic databases were retrieved to determine randomized controlled trials (RCTs) of vonoprazan for acid-associated diseases with any adverse effects and discontinuation. RESULTS: this systematic review and meta-analysis conforming to the selection criteria included 18 RCTs with a total of 7,932 participants. Compared with proton pump inhibitors, oral vonoprazan treatment showed no significant increase in the incidence of adverse effects (95 % CI = 0.987-1.095, p = 0.141). Diarrhea or loose stools analysis showed that there was a statistically significant difference between vonoprazan and proton pump inhibitors (PPIs) treatment (95 % CI = 0.661-0.966, p = 0.021). However, there was no significant difference in constipation, rash or eruption, nausea or vomiting, bloating or abdominal pain, dysgeusia, nasopharyngitis, neurological disorders, upper respiratory tract infection and abnormal investigations between vonoprazan and PPIs treatment. CONCLUSION: vonoprazan, which has better tolerability and safety, may significantly decrease diarrhea and loose stools in acid-related patients compared with PPIs. Our meta-analysis led to safer strategies for treating acid-related diseases. More high-quality studies with larger sample sizes are needed to further elucidate its efficacy and safety.

Key Findings

this systematic review and meta-analysis conforming to the selection criteria included 18 RCTs with a total of 7,932 participants. Compared with proton pump inhibitors, oral vonoprazan treatment showed no significant increase in the incidence of adverse effects (95 % CI = 0.987-1.095, p = 0.141). Diarrhea or loose stools analysis showed that there was a statistically significant difference between vonoprazan and proton pump inhibitors (PPIs) treatment (95 % CI = 0.661-0.966, p = 0.021). However,

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 7932
Age Range See abstract
Condition See abstract

MeSH Terms

  • Humans
  • Proton Pump Inhibitors
  • Constipation
  • Sulfonamides
  • Pyrroles
  • Diarrhea

Evidence Classification

  • Level: Meta Analysis
  • Publication Types: Meta-Analysis, Systematic Review, Journal Article
  • Vertical: potassium

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09